Programs that increase understanding and medical expertise in the field of coagulation.
Programs that expand awareness of the challenges that patients with hemophilia face and the role of innovations in hemophilia treatment.
Programs that improve diagnostic awareness and therapeutic assessment of von Willebrand disease.
Programs that provide education in areas of acquired bleeding and coagulation including: warfarin reversal (administration/dosing, acute care surgery, ICH and neurocritical care, emergency department management of bleeding), treatment of direct oral anticoagulant (DOAC)-associated bleeding, bleeding in cardiac surgery,
trauma/pre-hospital care, GI bleeding, transfusion medicine, and health economic aspects of blood management and concentrate administration.
Basic science programs with clinical correlation to acquired bleeding/coagulation will also be considered.
Programs that discuss efficacy and safety in special populations and neuromuscular disorders, especially Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Programs that improve diagnostic accuracy and awareness of appropriate diagnostic assessment criteria.
Programs that foster knowledge of appropriate management and assessment of patient outcomes.
Programs that expand the knowledge of patient management using immunoglobulin therapy via the intravenous and subcutaneous routes, including infusion training of healthcare professionals.
Programs that close clinical practice gaps in neuromuscular disease management.
Programs designed to expand awareness of antibody-mediated rejection in solid organ transplantation, especially renal transplantation and therapies for prophylaxis, treatment and their associated outcomes.
Programs intended to expand awareness of the research into novel therapies and cutting-edge advances in solid organ transplantation.
Programs that increase awareness of the burden of illness, unmet needs and outcomes in prophylaxis and/or treatment for acute graft-versus-host-disease and their effects on graft-versus-malignancy.
Programs aimed to expand awareness of the research into novel therapies and cutting-edge advances in hematopoietic cell transplantation.
Primary Immunodeficiency Disorders (PIDD)
Programs that raise awareness on disease burden and expand diagnosis, such as those focused on comorbidities among adults (e.g., chronic lung disease, autoimmune diseases).
Programs that expand the knowledge of therapeutic strategies for management of antibody deficiencies, including secondary immunodeficiencies.
Programs that improve diagnostic accuracy and awareness of appropriate assessment criteria.
Programs that foster knowledge and improve quality, delivery of care, utilization, and assessment of patient outcomes.
Programs that discuss innovations in the delivery of immunoglobulins.
Hereditary Angioedema (HAE)
Programs that enhance clinician’s knowledge of hereditary angioedema types I & II disease-state, epidemiology, diagnosis, and current/novel treatments for C1-Inhibitor deficiency.
Programs that cover the differential diagnosis of angioedema, its clinical signs and symptoms, pathophysiology and genetic basis of disease along with the various appropriate clinical triage and management strategies.
Programs that raise awareness around the HAE patient journey, real-world evidence, and quality of life aspects of their disease.
Programs pertaining to the management of HAE patients relevant to the managed care community.
Alpha-1 Antitrypsin Deficiency (AATD)
Programs that enhance the knowledge around the AATD disease state, educate diverse groups of healthcare professional about AATD.
Programs that address the clinical or health economic burden of disease, support advancements in AATD research, and explore the effect and safety of AATD therapies.